Histological evaluation of microfilled and conventional composite resins on monkey dental pulps

The pulpal responses to two micro-filled composite resins and a conventional composite resin were investigated in adult rhesus monkey teeth. All materials were randomly placed in unetched and unlined class V buccal cavity preparations. A total of 90 teeth were used in the study. Each material was evaluated at 3 days, 5 weeks and 8 weeks. Following perfusion, the teeth were prepared using routine histological procedures. The results indicated that the pulpal response to the microfilled and conventional composite resins were similar for all time periods, characterized by an initial slight to moderate response at 3 days, followed at 5 and 8 weeks by a zero to slight response with evidence of reparative dentine formation. Brown and Brenn staining for bacteria indicated positive staining reactions along the cavity wails of all teeth for all materials at each time period.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73366/1/j.1365-2591.1985.tb00453.x.pd

Offshoring and product innovation

Offshoring, Innovation, Incomplete contracts, Growth, Spillovers, Trade, F23, F12,

Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 108/kg with a median of 2.7 × 108/kg. The PB cell dose ranged from 0.02 to 77 × 10 8/kg with a median of 9.3 × 108/kg. The median dose for patients receiving BM (2.7 × 108/kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology